SEC 13F Intelligence

Natixis / REGN

Natixis’s Regeneron Pharmaceuticals Position

Does Natixis own Regeneron Pharmaceuticals (REGN)? Yes — 55.3K shares worth $43M (+0.15% of its 13F portfolio) as of Q1 2026, up from 33.8K shares the prior filed quarter.

Position Value
$43M
Q1 2026
Shares
55.3K
% of Portfolio
+0.15%
Quarters Held
27
currently held

Position History REGN

Reported value by quarter
Q1 ’19: $24MQ1 ’19Q2 ’19: $18MQ4 ’19: $2MQ1 ’20: $4MQ2 ’20: $80MQ2 ’20Q3 ’20: $6MQ4 ’20: $12MQ1 ’21: $13MQ3 ’21: $8MQ3 ’21Q4 ’21: $11MQ1 ’22: $92MQ2 ’22: $29MQ3 ’22: $20MQ3 ’22Q4 ’22: $20MQ1 ’23: $5MQ2 ’23: $9MQ3 ’23: $11MQ3 ’23Q4 ’23: $19MQ1 ’24: $5MQ2 ’24: $25MQ3 ’24: $57MQ3 ’24Q4 ’24: $65MQ1 ’25: $44MQ2 ’25: $38MQ3 ’25: $36MQ3 ’25Q4 ’25: $26MQ1 ’26: $43Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202655.3K$43M+0.15%
Q4 202533.8K$26M+0.09%
Q3 202563.8K$36M+0.17%
Q2 202572.2K$38M+0.17%
Q1 202569.4K$44M+0.24%
Q4 202491.0K$65M+0.40%
Q3 202454.6K$57M+0.32%
Q2 202424.2K$25M+0.15%
Q1 20245.5K$5M+0.03%
Q4 202322.0K$19M+0.14%
Q3 202312.8K$11M+0.08%
Q2 202312.6K$9M+0.07%
Q1 20235.7K$5M+0.04%
Q4 202228.4K$20M+0.11%
Q3 202228.4K$20M+0.09%
Q2 202249.7K$29M+0.11%
Q1 2022131.9K$92M+0.32%
Q4 202118.1K$11M+0.04%
Q3 202113.0K$8M+0.03%
Q1 202126.7K$13M+0.04%
Q4 202025.4K$12M+0.04%
Q3 202010.3K$6M+0.04%
Q2 2020128.0K$80M+0.62%
Q1 20209.0K$4M+0.03%
Q4 20195.7K$2M+0.01%
Q2 201958.3K$18M+0.14%
Q1 201958.4K$24M+0.15%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Natixis’s full portfolio or all institutional holders of REGN.